Earnings Results
Grace Therapeutics (NASDAQ:GRCE) reported quarterly earnings results on June 18, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $-0.06, beating the consensus estimate of $-0.21 by $0.15 per share. Revenue came in at , meeting the estimate of .
Company Overview
Grace Therapeutics's stock moved following the earnings release. The stock currently trades at $2.42 with a market capitalization of $47.5M.
Grace Therapeutics's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
The 71% beat relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Grace Therapeutics should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.
Grace Therapeutics Earnings History
| Quarter | EPS Actual | EPS Est. | Surprise |
| Q4 (Jun 2026) | $-0.06 | $-0.21 | +71.4% |
| Q3 (Feb 2026) | $-0.14 | $-0.27 | +48.1% |
| Q2 (Sep 2025) | $-0.06 | $-0.19 | +68.2% |
| Q1 (Jun 2025) | $-0.21 | $-0.22 | +6.4% |
Related Tools: Earnings Calendar | View GRCE Stock Page
Frequently Asked Questions
When does Grace Therapeutics report earnings?
Check the latest earnings dates on our GRCE earnings page or the Earnings Calendar.
Did GRCE beat earnings estimates?
See the full Q4 results including EPS actual vs estimate on our GRCE earnings page.